Canadian telemedicine specialist Stealth Health has expanded into the United States. The Toronto-based firm has launched two distinct business lines in the American market: a direct-to-patient telemedicine service; and an enterprise white-label platform for healthcare organisations.

The US expansion includes HIPAA-compliant technology and enterprise-grade infrastructure. Patients can access hormone optimisation, peptide therapy, and anti-ageing protocols through virtual consultations. The company stated that its Toronto-based research and development team will underpin development across US localised healthcare operations.

Stealth Health’s platform is designed to connect symptoms and lifestyle factors to uncover physiological drivers of health. The company aims to deliver personalised care at scale by combining targeted nutrition and advanced therapeutics. Healthcare organisations can now integrate these systems directly into their existing patient experiences.

Matthew Mazzuca, Chief Executive Officer of Stealth Health, said the dual-model approach allows the company to scale longevity care by reaching patients directly while providing technology to other healthcare brands. The white-label service enables clinics and wellness brands to launch branded telemedicine services featuring integrated clinical workflows and e-prescribing.

The company’s US infrastructure utilises a Management Services Organisation (MSO) structure to ensure regulatory compliance across all 50 states. The platform employs board-certified American physicians and licensed pharmacy partnerships to provide same-day shipping for custom prescriptions. The service incorporates the Metabolic Code assessment and TRIADS framework to deliver personalised wellness protocols based on blood testing and physiological biomarkers.